Elevated Capital Advisors LLC Has $354,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Elevated Capital Advisors LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 10.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,230 shares of the medical research company’s stock after acquiring an additional 114 shares during the period. Elevated Capital Advisors LLC’s holdings in Amgen were worth $354,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Southland Equity Partners LLC grew its position in Amgen by 2.3% during the fourth quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock valued at $443,000 after buying an additional 34 shares during the period. Quantum Financial Advisors LLC grew its position in Amgen by 1.3% during the fourth quarter. Quantum Financial Advisors LLC now owns 2,954 shares of the medical research company’s stock valued at $851,000 after buying an additional 38 shares during the period. Gray Wealth Management Inc. grew its position in Amgen by 3.3% during the second quarter. Gray Wealth Management Inc. now owns 1,206 shares of the medical research company’s stock valued at $268,000 after buying an additional 39 shares during the period. Hutchinson Capital Management CA grew its position in Amgen by 3.0% during the third quarter. Hutchinson Capital Management CA now owns 1,360 shares of the medical research company’s stock valued at $365,000 after buying an additional 39 shares during the period. Finally, Tiemann Investment Advisors LLC grew its position in Amgen by 3.1% during the second quarter. Tiemann Investment Advisors LLC now owns 1,334 shares of the medical research company’s stock valued at $296,000 after buying an additional 40 shares during the period. Institutional investors and hedge funds own 74.44% of the company’s stock.

Amgen Trading Down 1.0 %

AMGN stock opened at $268.87 on Friday. The company has a market capitalization of $144.09 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 2.59 and a beta of 0.58. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company’s 50 day moving average price is $294.66 and its two-hundred day moving average price is $279.49. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGNGet Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping the consensus estimate of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s revenue was up 19.8% compared to the same quarter last year. During the same period last year, the firm posted $4.09 earnings per share. As a group, analysts predict that Amgen Inc. will post 19.48 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 annualized dividend and a dividend yield of 3.35%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is 72.06%.

Analyst Ratings Changes

Several equities analysts recently weighed in on AMGN shares. Morgan Stanley reduced their price target on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $286.00 to $326.00 in a research report on Tuesday, December 19th. StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research report on Monday, March 11th. Royal Bank of Canada increased their target price on shares of Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Finally, Truist Financial reiterated a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $295.30.

Get Our Latest Analysis on AMGN

About Amgen

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Featured Articles

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.